CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Hengrui Pharma reports 88.9% rise in 2026 third-quarter profit on licensing deals

By Reuters News

BEIJING, Oct 27 (Reuters) - Jiangsu Hengrui Pharmaceuticals 600276.SS, China's biggest drugmaker by ‌market value, reported on Tuesday a rise of 88.9% in profit for the third quarter of 2026, driven by income from out-licensing deals.

  • Net profit of 2.5 billion yuan ($375 million) for the quarter ended September 30 was up from 1.3 billion a year ago

  • The figure beat one analyst's forecast of about 1.84 billion yuan in net income, LSEG data showed

  • Third-quarter operating revenue rose 21% to 9 billion yuan

  • Drugmakers in China are expanding licensing deals ​and developing new medicines as Beijing's centralised bulk buying programmes squeeze their revenue.

  • Global drugmakers are stepping up the search for China‑developed experimental medicines as they cut costs ahead of patent expiries.

  • Hengrui sells both generic medicines and those it has developed itself such as Hodgkin lymphoma drug AiRuiKa.

  • In August the company said it had completed 13 overseas business development deals since 2023.

  • In September Hengrui said Danish drugmaker Novo Nordisk NOVOb.CO would pay up to $2.6 billion for the rights to an experimental weight-loss pill.

  • By the end of the first half of 2026, 10 of Hengrui's innovative medicines were in Phase I clinical development.

  • Hengrui reported the third quarter results after the market closed

  • Shares are down about 23% so ⁠far ​this year, underperforming a fall of 2% in the ​Hang Seng Biotech Index .HSBIO

  • In the first half of 2026, 17 of Hengrui's clinical programs had advanced to Phase III, including its experimental psoriasis drug RSS0393 and breast cancer drug HRS-8080, its interim report showed

  • Hengrui said innovative drug sales revenue growth improved in the third quarter, but it expected a gap to persist for the full year between growth and a target set at the start of the year

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.